- Home
- RYDE vs SNGX Comparison
RYDE vs SNGX Comparison
Compare RYDE & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- SNGX
- Stock Information
- Founded
- RYDE 2014
- SNGX 1987
- Country
- RYDE Singapore
- SNGX United States
- Employees
- RYDE N/A
- SNGX N/A
- Industry
- RYDE
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- RYDE
- SNGX Health Care
- Exchange
- RYDE NYSE
- SNGX Nasdaq
- Market Cap
- RYDE 7.0M
- SNGX 6.5M
- IPO Year
- RYDE 2024
- SNGX 1987
- Fundamental
- Price
- RYDE $0.21
- SNGX $1.93
- Analyst Decision
- RYDE
- SNGX
- Analyst Count
- RYDE 0
- SNGX 0
- Target Price
- RYDE N/A
- SNGX N/A
- AVG Volume (30 Days)
- RYDE 149.2K
- SNGX 18.4K
- Earning Date
- RYDE 05-02-2025
- SNGX 05-09-2025
- Dividend Yield
- RYDE N/A
- SNGX N/A
- EPS Growth
- RYDE N/A
- SNGX N/A
- EPS
- RYDE N/A
- SNGX N/A
- Revenue
- RYDE $6,557,978.00
- SNGX $2,342.00
- Revenue This Year
- RYDE $21.13
- SNGX N/A
- Revenue Next Year
- RYDE $13.43
- SNGX N/A
- P/E Ratio
- RYDE N/A
- SNGX N/A
- Revenue Growth
- RYDE 3.27
- SNGX N/A
- 52 Week Low
- RYDE $0.18
- SNGX $1.68
- 52 Week High
- RYDE $22.49
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- SNGX 49.95
- Support Level
- RYDE N/A
- SNGX $1.86
- Resistance Level
- RYDE N/A
- SNGX $1.97
- Average True Range (ATR)
- RYDE 0.00
- SNGX 0.09
- MACD
- RYDE 0.00
- SNGX 0.01
- Stochastic Oscillator
- RYDE 0.00
- SNGX 70.59
About RYDE RYDE GROUP LTD
Ryde Group Ltd operates a technology platform that provides a range of ride-hailing, carpooling and delivery focused offerings in Singapore. The company operates in twos segments namely Mobility provides on-demand and scheduled carpooling and ride-hailing services, matching riders to its driver partners; and Quick Commerce provides on-demand, scheduled, and multi-stop parcel delivery services.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).